TNFRSF10B
Tumor necrosis factor receptor superfamily member 10B
As of the edition of 20 October 2026, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, UniProt O14763) has 7 drugs tested at it and 8 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O14763
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 13
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Blood and lymph; Immune system; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 34
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 4 |
| Stopped | 2 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Conatumumab | Went quiet | Phase 2 | none listed |
| Tigatuzumab | Went quiet | Phase 2 | none listed |
| Apomab | Went quiet | Phase 2 | none listed |
| Dulanermin | Went quiet | Phase 3 | none listed |
| Ozekibart | Active | Phase 2 | none listed |
| GEN1029 | Stopped | Phase 2 | none listed |
| Lexatumumab | Stopped | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Engaged | 1 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Roche | Route A |
| Daiichi Sankyo | Route A |
| Immunitybio | Route A |
The other 5 companies at TNFRSF10B
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at TNFRSF10B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.